Can an antibody aid neuropsychiatric SLE diagnosis?

Investigators compared a candidate biomarker across three diagnostic groups.

Category	Detail
Condition	Neuropsychiatric systemic lupus erythematosus (NPSLE)
Key Mechanisms	Cerebrospinal fluid antisuprabasin antibody
Target Population	Patients with systemic lupus erythematosus presenting with neuropsychiatric symptoms
Care Setting	Emergency department

Cerebrospinal fluid antisuprabasin antibody showed greater diagnostic accuracy for NPSLE compared to other tests.
The study included 148 patients with SLE who underwent lumbar puncture.
CSF antisuprabasin antibody had 81% sensitivity and 74% specificity at an optimal cutoff of 76.36 ng/mL.
A combined model of CSF antisuprabasin antibody, CSF white blood cell count, and serum antiribosomal P antibody yielded an area under the curve of 0.892.
The study calls for multicenter longitudinal studies to validate findings.

Use cerebrospinal fluid antisuprabasin antibody for identifying NPSLE among SLE patients with neuropsychiatric symptoms.

Patients with systemic lupus erythematosus and neuropsychiatric symptoms.

The posttreatment trajectory of CSF antisuprabasin antibody remains unknown.

Consider CSF antisuprabasin antibody testing in patients with SLE presenting with neuropsychiatric symptoms.

Clinical Scorecard: Can an antibody aid neuropsychiatric SLE diagnosis?